Tag: Survival

Clinically meaningful improvement seen in progression-free survival for transarterial chemoembolization plus lenvatinib and pembrolizumab

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer

Tool demonstrated generalizability through high predictive performance in international clinical cohort

Findings for primary tumors of 0.8 to 1.0 mm versus those <0.8 mm

Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients

Authors say further reductions will require new discoveries, adoption of emerging interventions

Benefit seen for stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles

Maximal survival benefit seen for smoking cessation treatment within six months of diagnosis

Improved three-year disease-free and recurrence-free survival seen with intensive chemotherapy regimen

UK-DTOP model shows marked improvement compared with traditional Kidney Donor Risk Index